In terms of provisions of Regulation 30 (read with Part A of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), this ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 3.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Colinz Laboratories reported audited standalone financial results for the quarter and year ended March 31, 2026. Revenue from operations declined to Rs. 613.61 Lakhs from Rs. 652.77 Lakhs in the previous year, representing a ~6% decrease. However, Profit After Tax (PAT) grew marginally from Rs. 49.66 Lakhs to Rs. 51.45 Lakhs (~3.6% YoY growth). EPS improved slightly to Rs. 2.04 from Rs. 1.97. The statutory auditors, Vora & Associates, issued an unqualified opinion on the financial statements. Cash and cash equivalents increased significantly to Rs. 852.91 Lakhs from Rs. 555.01 Lakhs, with positive operating cash flow of Rs. 254.11 Lakhs. The company is primarily engaged in pharmaceutical formulations manufacturing.
The ~6% revenue decline is a concern, though improved cost management helped maintain PAT growth. The strong cash position and positive operating cash flow are positive signals for shareholders. The unqualified audit opinion indicates clean financials with no material concerns.